David Elsley, MBA
President and Chief Executive Officer
Mr. David Elsley is a business leader with a proven track record of developing, financing and managing all aspects of corporate development in biotechnology and high-growth organizations.
In 1990, Mr. Elsley founded Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. Mr. Elsley assembled a team of management, directors and scientific advisors comprising industry professionals and thought leaders from North America and Europe.... read more
Mr. Elsley managed and directed Vasogen’s growth from start-up to an organization employing over 250 people with operations and R&D programs in Canada, the United States and Europe. He established the research and development infrastructure, partnerships, manufacturing capability, and corporate quality systems necessary to advance two anti-inflammatory therapies from concept to completion of international multi-center pivotal phase III clinical trials involving 2,500 patients. Vasogen went public on the TSX and the Nasdaq, raising over $200 million to support corporate development and reached a market capitalization of over US$ 1 billion.
Mr. Elsley holds a Master of Business Administration from the Richard Ivey School of Business, University of Western Ontario.
Andrew Hamer, MB, ChB
Chief Medical Officer
Dr. Andrew Hamer brings 30 years of experience in the global life sciences industry, medical affairs, and cardiology practice to the Company. Most recently he served as Executive Director, Global Development-Cardiometabolic at California-based Amgen Inc., where he led the Global Development group for Repatha®, the LDL cholesterol lowering PCSK9 inhibitor evolocumab, which generated revenues of almost US $900 million in 2020.... read more
As development lead, Dr. Hamer headed the Repatha® global evidence generation team collaborating with safety, regulatory, health economics, observational research, scientific communications, publications, medical affairs, and clinical operations teams to design and execute several multi-center clinical trials in support of FDA and international regulatory filings. Prior to his five-year tenure with Amgen, Dr. Hamer served for two years as VP Medical Affairs at Capricor Therapeutics Inc., where he was responsible for the development of novel therapeutics for heart disease and for the supervision of the clinical operations of the company, including clinical trial design and execution.
Prior to joining the life sciences industry, Dr. Hamer practiced cardiology and internal medicine in New Zealand for 19 years. His distinguished career in cardiology culminated as Chief Cardiologist at Nelson Hospital, Nelson Marlborough District Health Board, Nelson, while concurrently leading cardiac services nationally in New Zealand. Dr. Hamer graduated with a medical degree (MB, ChB) from the University of Otago, New Zealand, an internationally recognized medical school which recently ranked among the top twenty universities in the world in several medical subject categories. His clinical research training took place at various centres in New Zealand and London, UK, followed by a cardiology fellowship at Deaconess Hospital, Harvard Medical School, Boston. Dr. Hamer has co-authored many high-quality peer-reviewed scientific publications reflecting his considerable experience as a clinical trialist, having served as a principal or co-investigator for 40 multi-centre clinical trials in therapies for acute coronary syndrome, heart failure, hypertension, cholesterol disorders, atrial fibrillation, and diabetes.
Chris Waddick, MBA, CPA, CMA
Chief Financial Officer
Mr. Chris Waddick has thirty years of experience in financial and executive roles in the biotechnology and energy industries, with substantial knowledge of public company management and corporate governance, and in designing, building, and managing financial processes, procedures, and infrastructure. Mr. Waddick most recently served as Executive Vice President and Chief Financial Officer for a private Ontario energy company where he was retained by the shareholders to refinance the company and establish a new strategic direction, as well as the appropriate financial infrastructure. During his tenure, he implemented two corporate restructurings, drove substantial earnings growth, and significantly reduced both cost of capital and debt levels.... read more
Mr. Waddick spent more than twelve years at Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. While serving as Chief Financial Officer and Chief Operating Officer, the company grew from start-up to an organization employing over 250 employees that established the necessary systems and infrastructure to advance an anti-inflammatory therapy through to the completion of an international multi-center pivotal trial involving 2,500 patients. Vasogen went public on the TSX and the NASDAQ, raising over $200 million to support corporate development and reached a market capitalization of over US$ 1 billion. Prior to Vasogen, he held progressively senior financial positions at Magna International Inc. and Union Gas Limited.
Mr. Waddick is a CPA, CMA and earned a business degree from Wilfrid Laurier University and a Master of Business Administration from York University.
Bernard Lim, MIET, CEng (UK)
Chief Operating Officer
Bernard has a proven track record of over thirty years as a senior executive leading life sciences companies spanning biotechnology, diagnostics, medical devices, and high-technology companies in North America and Europe. He leads senior management teams through a sustained focus on strategy, rapid scale up and increasing talent depth to expand markets served. He was founder and CEO of a highly successful drug delivery company that he led from R&D through to commercialization and its eventual acquisition by Eli Lily.... read more
As Chair of the Board of Altus Assessments, he guided its spinout from the university and its subsequent growth to become market leader in US and Canada. As Chair of the Board and CEO of AndersDx (UK), he led its turnaround and growth. He is currently Chair of the Board of Front Line Medical Technologies, a vascular trauma company and board director of Aventamed (Ireland). Bernard was Senior Vice President, Operations for Vasogen, as well as head of UK operations for a technology multinational where he scaled its operations exponentially and delivered multifold improvements in quality and financial performance. He was CEO of a glaucoma, Alzheimer’s and an IVD company and prior to that head of R&D for a global neonatology and paediatrics company. Over his career, he has delivered exceptional results in fast growing independent growth companies and corporate roles focused on increasing innovation, accelerating and sustaining growth. In addition to his corporate roles, he serves as an external independent expert reviewer on public sector life science investment programs.
Andrea B. Parker, MSc, PhD
Director of Clinical Affairs
Dr. Parker is a senior executive with more than 30 years of experience in the execution of Phase I-IV research programs in the biomedical and medical device sectors. She was involved in the organization and execution of many large-scale international clinical trials, specializing in cardiovascular disease, pain management, and imaging techniques. She worked in academic settings, as well as for Contract Research Organisations and for Industry.... read more
Prior to joining Cardiol Therapeutics Inc., she was Chief Scientific Officer at the Peter Munk Cardiac Centre, University Health Network in Toronto, where she provided scientific support for industry-sponsored and investigator-initiated trials, including clinical team and committee management, budget allocation, and grant writing support (2010 – 2019).
Dr. Parker also served as Vice President, Clinical Development for Fralex Therapeutic Inc., a medical device company in the therapeutic area of pain management.
She held the position Director, Clinical Affairs at Vasogen Inc., where she was responsible for the execution of two pivotal trials, involving more than 200 sites in the U.S., Canada, and Europe.
Prior to Vasogen Inc., Dr. Parker was the Managing Director of the offices in Boston and in Toronto for a Contract Research Organization (Société de la Recherche Cardiologique) based in Switzerland. She was responsible for day-to-day management of the company, as well as setting strategic directions for all clinical affairs services. This included building infrastructure and framework to further expand the company’s projects, as well as overseeing staff.
Dr. Parker graduated with a Master of Science degree in Chemistry from the University of Leipzig (Germany); she holds a MSc in Clinical Epidemiology from Harvard School of Public Health and a PhD in Medical Sciences from the University of Toronto.
Anne Tomalin, BA, BSc, RAC
Director of Regulatory Affairs
Ms Tomalin has a strong background in business, government, regulations, and reimbursement policies and has practiced exclusively in regulatory affairs since 1971. In September 2013, she founded TPIreg Inc., a Regulatory Affairs and Quality Assurance company providing consulting services for Canada and the United States to the healthcare industry. TPIreg Inc. was acquired by Innomar Strategies in 2019. Prior to TPIreg, in September 1996, Ms. Tomalin founded CanReg Inc. which became Canada’s largest Regulatory Affairs consulting firm with more than 100 staff, assisting clients with Health Canada, FDA, and EMA matters, before being acquired by United Health Inc. in December 2009. Prior to this, she was employed by Searle Canada for 20 years as Business Unit Director.... read more
Ms. Tomalin has participated in the Regulatory Initiatives Advisory Committee for the Pharmaceutical Manufacturers Association Canada (PMAC). She has also served on the executive of the Pharmaceutical Sciences Group (PSG) and the Canadian Association of Pharmaceutical Regulatory Affairs (CAPRA). Ms. Tomalin currently sits on the Advisory Board for CAPRA in Canada and has also chaired the Manitoba, Saskatchewan, and Ontario Committees for the PMAC, now Innovative Medicines Canada (IMC). She is engaged in teaching several regulatory courses to industry, has been an instructor at Humber College, and currently serves on their Advisory Panel. She has published numerous papers on regulatory affairs and issues.
Ms. Tomalin is a graduate of York University with a BA in English and BSc in Chemistry and holds certifications from the Regulatory Affairs Professional Society in US, European, and Canadian Regulatory Affairs.
Blagoja Ristevski, BSc, CHE
Director of Chemical Engineering and Manufacturing
Mr. Blagoja Ristevski graduated with a BSc in Chemical Engineering and Inorganic Chemistry from the University of Ss ‘Cyril and Methodius’, Skopje, Macedonia, and pursued postgraduate research on natural biopolymers as drug carriers at King’s College London, UK. For 20 years he was involved in the research and discovery of active drug molecules, drug delivery technologies, and manufacturing methodologies for finished drug products at several biopharmaceutical companies.... read more
Mr. Ristevski has over 25 years of senior executive level experience in the Canadian pharmaceutical and biotechnology industry including positions with Astra, Hyal Pharmaceuticals, Delex Therapeutics (now part of Gilead), and the Advanced Medical Research Institute of Canada where he was VP of product development. He has a track record of success in licensing new products with multiple successful IND and NDA applications, including for Solaraze gel. He has an extensive network across the North American biopharmaceutical industry and is experienced in the assessment and development of therapeutic, diagnostic, and medical device products. In 2009, he founded Remetar Inc., a company involved in licensing early-stage pharmaceutical projects which have included a therapeutic for the regulation of intraocular pressure and a project focusing on regulating low-grade inflammation by targeting inflammatory cytokine receptors.